EAM
RLAY icon

Exome Asset Management’s Relay Therapeutics RLAY Stock Holding History

Exome Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$889K Sell
47,531
-230,771
-83% -$3.35M 0.55% 47
2026
Q1 		$2.77M Buy
+278,302
New +$2.49M 1.43% 32
2025
Q1 		– Sell
-1,083,487
Closed -$4.46M – 78
2024
Q4 		$4.46M Buy
1,083,487
+668,858
+161% +$3.64M 3.35% 6
2024
Q3 		$2.94M Buy
+414,629
New +$3.1M 1.98% 21

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Exome Asset Management's RLAY Position: Q2 2026 in Review

Exome Asset Management reduced its Relay Therapeutics (RLAY) stake by 83% in Q2 2026, selling an estimated $3.35M and leaving 47,531 shares worth $889K. The position accounts for 0.55% of the portfolio, ranked #47.

Exome Asset Management first reported a position in RLAY in Q3 2024 and has held it in 4 quarters since. The position peaked at $4.46M in Q4 2024. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Exome Asset Management held 47,531 shares of Relay Therapeutics worth $889K as of Q2 2026.
  • Exome Asset Management sold 230,771 Relay Therapeutics shares in Q2 2026, an estimated $3.35M.
  • Relay Therapeutics made up 0.55% of Exome Asset Management's portfolio in Q2 2026, its #47 holding.
  • Exome Asset Management first reported a position in Relay Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Exome Asset Management's Relay Therapeutics position peaked at $4.46M in Q4 2024.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.